{"id":"hl036-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HL036 is a topical eye drop formulation in Phase 3 development by HanAll BioPharma. Without disclosed mechanism details, the drug appears to target ocular surface conditions, potentially through anti-inflammatory signaling, mucin secretion enhancement, or tear film stabilization. The ophthalmic solution format indicates local delivery to the eye surface.","oneSentence":"HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:48.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease or ocular surface disease (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06400589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease","status":"SUSPENDED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-05-01","conditions":"Dry Eye","enrollment":750},{"nctId":"NCT03334539","phase":"PHASE2","title":"A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2017-11-05","conditions":"Dry Eye","enrollment":150},{"nctId":"NCT05109702","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2021-11-18","conditions":"Dry Eye","enrollment":260},{"nctId":"NCT04633213","phase":"PHASE3","title":"A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye","status":"UNKNOWN","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","startDate":"2021-02-24","conditions":"Dry Eye","enrollment":674},{"nctId":"NCT03846453","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2019-03-10","conditions":"Dry Eye","enrollment":637},{"nctId":"NCT02717208","phase":"PHASE1","title":"Phase 1 Study for Safety and Tolerability of HL036","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2016-02","conditions":"Dry Eye","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tanfanercept"],"phase":"phase_3","status":"active","brandName":"HL036 Ophthalmic Solution","genericName":"HL036 Ophthalmic Solution","companyName":"HanAll BioPharma Co., Ltd.","companyId":"hanall-biopharma-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms. Used for Dry eye disease or ocular surface disease (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}